Cryoport, Inc. (NASDAQ:CYRX) Short Interest Update

Cryoport, Inc. (NASDAQ:CYRX) was the recipient of a large decrease in short interest during the month of December. As of December 31st, there was short interest totalling 2,080,000 shares, a decrease of 5.5% from the December 15th total of 2,200,000 shares. Based on an average daily trading volume, of 405,400 shares, the days-to-cover ratio is currently 5.1 days. Currently, 4.4% of the shares of the company are sold short.

Insider Buying and Selling

In other news, CEO Jerrell Shelton sold 50,000 shares of Cryoport stock in a transaction that occurred on Thursday, November 21st. The stock was sold at an average price of $6.51, for a total transaction of $325,500.00. Following the sale, the chief executive officer now owns 731,897 shares of the company’s stock, valued at approximately $4,764,649.47. The trade was a 6.39 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Ramkumar Mandalam sold 7,369 shares of the stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $7.46, for a total value of $54,972.74. Following the completion of the transaction, the director now directly owns 59,497 shares of the company’s stock, valued at $443,847.62. This trade represents a 11.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 109,869 shares of company stock worth $735,673 in the last three months. 10.10% of the stock is owned by insiders.

Institutional Investors Weigh In On Cryoport

Several hedge funds have recently made changes to their positions in the company. Avanza Fonder AB purchased a new position in Cryoport during the 4th quarter valued at about $64,000. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Cryoport during the third quarter worth approximately $82,000. Hsbc Holdings PLC purchased a new position in Cryoport during the second quarter valued at approximately $92,000. Intech Investment Management LLC acquired a new position in Cryoport in the 3rd quarter valued at approximately $105,000. Finally, The Manufacturers Life Insurance Company lifted its position in Cryoport by 9.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 17,683 shares of the company’s stock worth $122,000 after buying an additional 1,534 shares in the last quarter. Hedge funds and other institutional investors own 92.90% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on CYRX shares. Needham & Company LLC reiterated a “buy” rating and set a $11.00 price objective on shares of Cryoport in a research note on Friday. Guggenheim assumed coverage on shares of Cryoport in a report on Thursday, December 19th. They issued a “buy” rating and a $11.00 price target for the company. Roth Mkm lowered their price objective on shares of Cryoport from $18.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday, November 8th. Finally, UBS Group boosted their target price on shares of Cryoport from $7.00 to $9.00 and gave the stock a “neutral” rating in a report on Friday, October 18th. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, Cryoport presently has a consensus rating of “Moderate Buy” and an average price target of $12.29.

Cryoport Stock Up 0.1 %

CYRX stock opened at $7.50 on Friday. Cryoport has a one year low of $5.32 and a one year high of $20.10. The firm has a 50-day moving average of $7.68 and a two-hundred day moving average of $7.86. The company has a quick ratio of 5.32, a current ratio of 5.70 and a debt-to-equity ratio of 0.48.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.